Publications by authors named "Mark Bangs"

Claim this Profile
T
Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment.
Miguel J A Láinez, Jean Schoenen, Chad Stroud, Jennifer Bardos, Mark Bangs

Headache· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies.
Mark E Bangs, David Kudrow, Shufang Wang, Tina M Oakes, Gisela M Terwindt

BMC Neurol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies.
Mark E Bangs, David Kudrow, Shufang Wang, Tina M Oakes, Gisela M Terwindt

BMC Neurol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term, Open-Label, Safety Study of Edivoxetine Monotherapy in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
Emel Serap Monkul Nery, Mark Bangs, Peng Liu, Jonna Ahl, David Perahia

J Child Adolesc Psychopharmacol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy outcomes from 3 clinical trials of edivoxetine as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.
Susan G Ball, Margaret B Ferguson, James M Martinez, Beth A Pangallo, E Serap Monkul Nery, Mark Bangs

J Clin Psychiatry· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term, Open-Label, Safety Study of Edivoxetine 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment.
Susan G Ball, Sarah Atkinson, JonDavid Sparks, Mark Bangs, Celine Goldberger

J Clin Psychopharmacol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder.
Graham J Emslie, Thomas G Wells, Apurva Prakash, Qi Zhang, Beth A Pangallo, Mark E Bangs

J Child Adolesc Psychopharmacol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor antidepressants for patients with major depressive disorder.
James M Martinez, Margaret B Ferguson, Beth A Pangallo, Tina M Oakes, JonDavid Sparks, Mark Bangs

Drugs Context· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The risk of bleeding with duloxetine treatment in patients who use nonsteroidal anti-inflammatory drugs (NSAIDs): analysis of placebo-controlled trials and post-marketing adverse event reports.
David G Perahia, Mark E Bangs, Qi Zhang, Yingkai Cheng, Jonna Ahl

Drug Healthc Patient Saf· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of falls in older patients treated with duloxetine: a secondary analysis of a 24-week randomized, placebo-controlled trial.
J Craig Nelson, Tina M M Oakes, Peng Liu, Jonna Ahl, Mark E Bangs

Prim Care Companion CNS Disord· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A cohort study of the risk of seizures in a pediatric population treated with atomoxetine or stimulant medications.
Andrew T McAfee, Joan Landon, Meghan Jones, Mark E Bangs, Nayan Acharya

Pharmacoepidemiol Drug Saf· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of atomoxetine on Tanner stage sexual development in children and adolescents with attention deficit/hyperactivity disorder: 18-month results from a double-blind, placebo-controlled trial.
Paula T Trzepacz, Thomas J Spencer, Shuyu Zhang, Mark E Bangs, Michael M Witte

Curr Med Res Opin· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atomoxetine and cerebrovascular outcomes in adults.
Crystal N Holick, Bruce R Turnbull, Meghan E Jones, Saadia Chaudhry, Mark E Bangs

J Clin Psychopharmacol· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD.
Craig Donnelly, Mark Bangs, Paula Trzepacz, Ling Jin, Shuyu Zhang

J Am Acad Child Adolesc Psychiatry· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder.
Mark E Bangs, Ling Jin, Shuyu Zhang, Durisala Desaiah, Albert J Allen

Drug Saf· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
Mark E Bangs, Philip Hazell, Marina Danckaerts, Peter Hoare, David R Coghill

Pediatrics· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 allele.
Yi M Cui, Choo H Teng, Alan X Pan, Eunice Yuen, Kwee P Yeo, Mark E Bangs

Br J Clin Pharmacol· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression.

J Child Adolesc Psychopharmacol· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Humberto Quintana, Edward A Cherlin, David A Duesenberg, Mark E Bangs, Janet L Ramsey

Clin Ther· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis